RXi Pharmaceuticals Corporation (NASDAQ: RXII) and privately-held MirImmune LLC, today announced that they have entered into an exclusive license agreement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE